Semaglutide for Type 2 Diabetes
Original indication for GLP-1 drugs. Semaglutide (Wegovy/Ozempic) is a GLP-1 receptor agonist shown to produce 15% average body weight loss in clinical trials.
How Semaglutide Helps with Type 2 Diabetes
Semaglutide mimics the GLP-1 hormone to reduce appetite and slow stomach emptying, leading to significant weight loss. For patients with type 2 diabetes, this weight loss translates to meaningful improvements in condition-specific outcomes.
Original indication for GLP-1 drugs. The STEP clinical trial program demonstrated that semaglutide 2.4mg weekly produces an average weight loss of 15% of body weight over 68 weeks, with additional benefits for metabolic health markers.
Clinical Evidence for Type 2 Diabetes
Type 2 Diabetes affects 37 million Americans. Research shows that GLP-1 medications like semaglutide address both the weight component and the underlying metabolic dysfunction associated with type 2 diabetes. Patients with this condition often see compounding benefits from weight loss, including improved energy, mobility, and overall quality of life.
Semaglutide Dosing for Type 2 Diabetes
Semaglutide is taken as a once-weekly subcutaneous injection. The standard titration starts at 0.25mg and gradually increases to the maintenance dose of 2.4mg over 16-20 weeks. Dosing is the same regardless of the indication — your provider will monitor your response and adjust timing as needed.
Cost of Semaglutide for Type 2 Diabetes
Compounded semaglutide costs $149-399/month through telehealth providers. Brand-name Wegovy costs $1,300+/month without insurance. Many patients with type 2 diabetes have associated comorbidities that improve insurance coverage chances.